ABT-737

Catalog No.S1002

ABT-737 Chemical Structure

Molecular Weight(MW): 813.43

ABT-737 is a BH3 mimetic inhibitor of Bcl-xL, Bcl-2 and Bcl-w with EC50 of 78.7 nM, 30.3 nM and 197.8 nM in cell-free assays, respectively; no inhibition observed against Mcl-1, Bcl-B or Bfl-1. Phase 2.

Size Price Stock Quantity  
In DMSO USD 384 In stock
USD 120 In stock
USD 200 In stock
USD 570 In stock
USD 970 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 91 Publications

17 Customer Reviews

  • Cardiomyocytes transduced with or without Ad-Mst1 were treated with ABT-737 (0, 0.1, 1, 10 uM) for 12 hours. Representative immunoblots with antibodies to p62/SQSTM1, LC3 and GAPDH are shown.

    Nat Med 2013 19(11), 1478-88. ABT-737 purchased from Selleck.

    BCL-XL mediates human neutrophil survival. PMNs were preincubated with the BH3 mimetic ABT-737 (1–10 μM), then cultured in normoxia (gray bars) with or without GM-CSF (500 U/ml) or hypoxia (white bars)or 20 hours, and apoptosis was assessed by morphology (n = 4).

     

     

    J Clin Invest 2011 121, 1053-1063. ABT-737 purchased from Selleck.

  • Release of mitochondrial cytochrome c and loss of mitochondrial membrane potential after exposure to ABT-737 (100nM) for 2 hours were assessed by immunohistochemistry and staining with TMRE (red, top panels) and anti-CD41/FITC (green, top panels). Bar represents 5 um. Note that control cells display spreading on glass slides, whereas ABT-737-treated cells do not.

    Blood 2011 17(26), 7145-54. ABT-737 purchased from Selleck.

    Platelets were incubated in HBS with or without ABT-737 (100nM) for 2 hours before analysis by immunohistochemistry and confocal microscopy. Actin was stained using phalloidin/Alexa-488 (green), and tubulin was stained using anti-tubulin/phycoerythrin (red). Bar represents 5 uM.

    Blood 2011 17(26), 7145-54. ABT-737 purchased from Selleck.

  • (B) The sensitivity (LD50) of CLL cells, assessed by annexin V staining after 48 h of treatment with ABT‐737, ABT‐263 or ABT‐199, was plotted against the pBcl‐2/Bcl‐2, Mcl‐1/Bcl‐2 and (pBcl‐2 + Mcl‐1)/Bcl‐2 ratios. Relative protein quantification was carried out with kodak carestream molecular imaging software and normalized to β‐actin. Spearman's correlation (r) and P values are shown. Data shown are representative of five independent experiments.

    Br J Pharmacol, 2016, 173(3):471-83. ABT-737 purchased from Selleck.

    Analysis of SW480 and SW620 cell sensitivity to the BH3-mimetic ABT-737. (a, b) Percentage of apoptosis in adherent or suspended SW480 (a) or SW620 (b) cells cultured in the presence (ABT-737) or absence (ctrl) of ABT-737 (1 uM).

    Cell death dis 2013 4, e801. ABT-737 purchased from Selleck.

  • Bcl-XL/Bcl-2 inhibitor ABT-737 aggravates the proapoptotic effects of IL-1IFN-. INS-1E cells were transfected with single or smart Pool PUMA siRNAs and exposed to ABT-737 for 24 h. At this time point, cell death was measured by HO/PI, n  3. *, p  0.05; **, p  0.01.
     

     

     

    J Biol Chem 2010 285, 19919-19920. ABT-737 purchased from Selleck.

    Effect of ABT-737 on the cell viability of CCRF-CEM cells by treatments of AY4 (10 μg/ml), TRAIL (0.5 μg/ml), SAHA (1 μM),VPA (1 mM), or ABT-737 (10 μM) alone or in combination for 24 h prior to MTT assay.

     

     

    Apoptosis 2010 15, 1256-1269. ABT-737 purchased from Selleck.

  • Effects of ABT-737 and RES, applied alone and in combination, on the viability of MOLT-4 cells.

    Toxicol In Vitro, 2017, 42:38-46. ABT-737 purchased from Selleck.

    Upper panel ABT-737 inhibits TFK-1 and EGI-1 cell growth.Cells were exposed to ABT-737 at a concentration ranging from 1 to 50 lM. Following 72 h of incubation, growth inhibition was analyzed by crystal violet assay. Dose–effect plot of ABT-737 treatment is presented.

     

     

    Cancer Chemoth Pharm 2011 67, 557-567. ABT-737 purchased from Selleck.

  • Lower panel detection of PARP-1, cleaved caspase-9 and caspase-3, BCL-2 and MCL-1 in TFK-1 and EGI-1 cells after 72 h of ABT-737 treatment (1, 3, 10, 25,50 μM). Cell lysates were analyzed on Western blotting.

     

     

    Cancer Chemoth Pharm 2011 67, 557-567. ABT-737 purchased from Selleck.

    3 μM ABT737 inhibited growth and viability of TF-1 cells and potentiated proapoptotic effects of 1 μM BIO after 72 hours treatment. TF-1 cells treated with both drugs exhibited more apoptotic cells compared to those treated with each single drug. ABT737 abrogated the protection from BIO-induced apoptosis provided by MS5 coculture.

     

     

    Exp Hematol 2010 38, 908-921. ABT-737 purchased from Selleck.

  • GSIXII synergized with ABT-737 to trigger apoptosis in breast cancer cells . Breast cancer cell lines were incubate d for 48 hours with 10μM GSIXII or DMSO (Ct) in combination or not with ABT-737, 1 μM. Then apoptosis was evaluated with Apo2.7 or Annexin-V staining and flow-cytometry analysis. Represented data are the means of positive cells ± SEM, from three independent experiments.(A) Suboptimal concentrations of GSIXII (5 μM) and 1 μM ABT-737 were used alone or in combination in MFU assay in MCF7 and BT549 cell lines. Results were obtained from three independent experiments and compared with mock-treated condition. (B) The 20 μM SAHM1 was used alone or in combination in MFU assay in MCF7 and BT549 cell lines. Results were obtained from three independent experiments and compared with the mock-treated condition.

    Biochem Biophys Res Commun 2013 408, 344-9. ABT-737 purchased from Selleck.

    Apoptosis induced by BCL2-inhibitors in P-glycoprotein expressing cells. MDCKII wild type or MDR1 cells were exposed to different concentrations of ABT-737 (C) or ABT-263 (D) for 24 h before apoptosis was assessed by flow cytometry using externalization of phosphatidylserine.

    Biochem Biophys Res Commun 2012 408, 344-9. ABT-737 purchased from Selleck.

  • The combined use of ABT-737 and sorafenib changes the apoptotic effect. MC-3 cells were treated with the indicated compounds for 48 h. (A) Nuclear condensation and fragmentation were evaluated in DAPI-stained cells as described in the Materials and Methods (X400). (B) Live (green) and dead (red) cells were qualified using the Live/dead assay kit as described in the Materials and Methods (X200). (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)

    Arch Oral Biol, 2017, 73:1-6. ABT-737 purchased from Selleck.

    MEF wt and MEF Mcl-1 ko mice activating active caspase-3 using 1um ABT for 24h

     

     

    Dr. Arnim Weber of Medizinische Mikrobiologie und Hygiene Universitatsklinikum Freiburg. ABT-737 purchased from Selleck.

  • MDB-MA-231 cells were exposed to 30 um cisplatin in the absence or in thepresence of 100nm ABT-737.The cell were stained with Hoechst 33342,MitoTracker Red and Yo-pro-1.

     

     

    Dr. Zhang of Tianjin Medical University. ABT-737 purchased from Selleck.

Purity & Quality Control

Choose Selective Bcl-2 Inhibitors

Biological Activity

Description ABT-737 is a BH3 mimetic inhibitor of Bcl-xL, Bcl-2 and Bcl-w with EC50 of 78.7 nM, 30.3 nM and 197.8 nM in cell-free assays, respectively; no inhibition observed against Mcl-1, Bcl-B or Bfl-1. Phase 2.
Features First-generation inhibitor of anti-apoptotic Bcl-2 proteins.
Targets
Bcl-2 [1]
(Cell-free assay)
Bcl-xL [1]
(Cell-free assay)
Bcl-w [1]
(Cell-free assay)
Bcl-B [1]
(Cell-free assay)
30.3 nM(EC50) 78.7 nM(EC50) 197.8 nM(EC50) 1.82 μM(EC50)
In vitro

ABT-737 shows low activity to Bcl-B and no effects to Mcl-1 and BFL-1. ABT-737 is sensitive to HL60, KG1 and NB4 cells with IC50 of 50 nM, 80 nM and 80 nM, respectively. ABT-737 induces apoptosis in HL60 cells, which due to decreased Bcl-2/Bax heterodimerization and has no effect on cell cycle distribution. ABT-737 also induces cytochrome c release from purified mitochondria and promotes conformational changes in Bax that are associated with apoptosis. [1] Resistant cells (Hela and MCF-7) can be sensitized to ABT-737 by approaches that down-regulate, destabilize, or inactivate Mcl-1. ABT-737 also causes Bax/BAK-dependent cytochrome c release only when Mcl-1 has been neutralized. [2] ABT-737 displaces Bim from Bcl2's BH3-binding pocket, allowing Bim to activate Bax, induce mitochondrial permeabilization, and rapidly commit the primary chronic lymphocytic leukemia (CLL) cells to death. [3] Knockdown of Mcl-1 with siRNA sensitizes two resistant SCLC cell lines H196 and DMS114 to ABT-737 by enhancing the induction of apoptosis. Likewise, up-regulation of Noxa sensitizes H196 cells to ABT-737. ABT-737 inhibits proliferation and induces apoptosis in many SCLC cell lines including NCI-H889, NCI-H1963, NCI-H1417, NCI-H146 and etc. Bcl-2 and Noxa may contribute mechanistically to the cellular response to ABT-737 in NCI-H146 cells. [4] A recent study shows that ABT-737 significantly induces apoptosis in HTLV-1 infected T-cell lines as well as in fresh ATLL cells. [5]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
OCI-Ly1  MYnD[YxtKF[rYXLpcIl1gSCDc4PhfS=> M4\CWVI2OCCwTdMg NFXqbFA4OiCq M1P5eWROW09? Mne2Z4F2e2WmIEm3KUBtd3O|IH;mJJZq[WKrbHn0fUBqdiClZXzsd{B1emGwc3\lZ5Rm\CC5aYToJGJEVDZic3nSUmE> MkL6NlY3PTd{OEi=
KG1a MWXD[YxtKF[rYXLpcIl1gSCDc4PhfS=> M3jYfFAuOTBizszN NGn3T4MzPCCq MWLEUXNQ MXvJR|UxRTdwNkig{txONCCmZXPy[YF{\XNiY3XscEB3cWGkaXzpeJkhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> NHizXmIzPjV3MkexNi=>
Kasumi-1 NEjUSpdE\WyuIG\pZYJqdGm2eTDBd5NigQ>? M{HQOlAuOTBizszN NW\HRVlxOjRiaB?= NXfsN5Y5TE2VTx?= MW\JR|UxRTRwOEeg{txONCCmZXPy[YF{\XNiY3XscEB3cWGkaXzpeJkhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> MmPpNlY2PTJ5MUK=
KG1a MXPBdI9xfG:|aYOgRZN{[Xl? NXTPRoNlOC1zMDFOwG0> Mn:0NlQhcA>? M3fsWWROW09? M1LORolv\HWlZYOgZ4VtdCCjcH;weI9{cXNiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MYCyOlU2OjdzMh?=
Kasumi-1 NEfuN3hCeG:ydH;zbZMhSXO|YYm= M4nsVlAuOTBizszN NEP0bo4zPCCq M1TFfGROW09? NHjUPJhqdmS3Y3XzJINmdGxiYYDvdJRwe2m|IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ NVLWe3BXOjZ3NUK3NVI>
MC-3  NILFcFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF:wV5Q2NzFyL{KwJO69VQ>? NHHrUVQzPCCq MYjEUXNQ M4jWNIlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz NHHyeIMzPjR2N{[xOS=>
HN22  NE\xT4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVfC[oc3Oi53L{euOU8zOi53IN88US=> MXyyOEBp M2DXUmROW09? NWnPPJNKcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MmW4NlY1PDd4MUW=
MC-3  NEPqUmRCeG:ydH;zbZMhSXO|YYm= MoDrOU8yOC9{MDFOwG0> NWrCPVhpOjRiaB?= MWXEUXNQ NGnKUnNqdmS3Y3XzJINie3Cjc3WtcYVlcWG2ZXSgZZBweHSxc3nz MWKyOlQ1PzZzNR?=
HN22  NXHTTpFlSXCxcITvd4l{KEG|c3H5 NYHrU2o4Oi53L{euOU8zOi53IN88US=> M2jVeFI1KGh? NVrzZVVCTE2VTx?= MWXpcoR2[2W|IHPhd5Bie2VvbXXkbYF1\WRiYYDvdJRwe2m| MknTNlY1PDd4MUW=
MOLT-4 MlPOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWf1dHhQOTBvNUCwNEBvVQ>? NV7RRlV4PzJiaB?= MWXEUXNQ M4DnTmlEPTB;MD6xPVgh|ryP MYKyOlM6OjN|Mh?=
RS4;11 NH\QRnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYTmdVNHOTBvNUCwNEBvVQ>? M36zPFczKGh? MXXEUXNQ MYDJR|UxRTBwMECyJO69VQ>? NIHmTW8zPjN7MkOzNi=>
JURKAT Mo[2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1HEfFExNTVyMECgcm0> MXW3NkBp MV7EUXNQ NH2y[5dKSzVyPU[2JO69VQ>? Mnj6NlY{QTJ|M{K=
CEM R M2Xvemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoLnNVAuPTByMDDuUS=> M4LRc|czKGh? MnP6SG1UVw>? MX\JR|UxRTVwNDFOwG0> MnnzNlY{QTJ|M{K=
CEM S NYLlSnNpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYGxNE02ODByIH7N NGDUOG44OiCq NVrONHdyTE2VTx?= MXTJR|UxRTF{LkGg{txO Mk[1NlY{QTJ|M{K=
MOLT-4 MV3BdI9xfG:|aYOgRZN{[Xl? NGfJNlAyOC1zMECwJI5O NEjrZpAzPCCq NEHvcm1FVVOR Ml3wZ4F2e2W|IITo[UBkdGWjdnHn[UBw\iCEY3ytNkBidmRidHjlJIRwf26{ZXf1cIF1cW:wIH;mJGJkdC26TDDhcoQhVWOuLUG= MXeyOlM6OjN|Mh?=
CEM S NH73XWtCeG:ydH;zbZMhSXO|YYm= NIXEOFgyOC1zMECwJI5O MoCyNlQhcA>? NHHxUJFFVVOR NIq4SmVk[XW|ZYOgeIhmKGOuZXH2ZYdmKG:oIFLjcE0zKGGwZDD0bIUh\G:5boLl[5Vt[XSrb36gc4YhSmOuLYjMJIFv\CCPY3ytNS=> M1nw[lI3Ozl{M{Oy
JURKAT Ml3DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{S2UFExOC1zMECwJI5O NGTnNHg1QCCq Mke4SG1UVw>? MmTLTWM2OD17NUZCtVkvOyCwTR?= NHrKTGMzPjF5MkK2PS=>
LOUCY M{DWbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX[xNFAuOTByMDDuUS=> MXi0PEBp MWrEUXNQ MXzJR|UxRTN{LklCtVExNjlibl2= NH33UVgzPjF5MkK2PS=>
WM-115 M4n4bGNmdGxiVnnhZoltcXS7IFHzd4F6 MYOxNFDDqG6P MmDyO|IhcA>? NWPHNnZt\W6qYX7j[ZMh[3W{Y4XtbY4ucW6mdXPl[EBidnSrLYP1dpZqfmGuwrC= MViyOlEyPjd5Nh?=
B16 NIO3c|lE\WyuIG\pZYJqdGm2eTDBd5NigQ>? M4nvO|ExOMLibl2= NUTp[lZXPzJiaB?= MV;lcohidmOnczDjeZJkfW2rbj3pcoR2[2WmIHHueIkue3W{dnn2ZYzDqA>? Mon4NlYyOTZ5N{[=
HL-60  NUmzXopVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4CyUVczKGh? NYnne4xIUUN3MNMgQUAyOC55IH7N NY\kWlV1OjZyNEW2NFk>
MOLM-13  NHjXfHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnyxO|IhcA>? MWLJR|UxyqB;IEK3Mlkhdk1? MmjONlYxPDV4MEm=
OCI-AML3 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV23NkBp NFTwNW9KSzVywrC9JFE6PTBibl2= MYGyOlA1PTZyOR?=
BCWM.1 NHHEO2FCeG:ydH;zbZMhSXO|YYm= MoP4NE0yNjZizszN M3\EWlI1KGh? M3LncYlv\HWlZYOgZ4VtdCCjcH;weI9{cXN? NHnic2IzPTh7M{K5NC=>
MWCL-1 NVPOd4lsSXCxcITvd4l{KEG|c3H5 NUKwO5RWOC1zLk[g{txO MVuyOEBp MkG2bY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? Ml\BNlU5QTN{OUC=
MM.1s NFTKOlRCeG:ydH;zbZMhSXO|YYm= NUO0[2xHOC1zLk[g{txO MWeyOEBp NX\sTmRvcW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= MViyOVg6OzJ7MB?=
HCT116 MoLMSpVv[3Srb36gRZN{[Xl? NHXsS3Y{NzFyIN88US=> NELtcXEyOsLiaNMg NEj1b2RFVVOR MYPpcoR2[2W|IHGg[I9{\S2mZYDlcoRmdnRiaX7jdoVie2ViaX6gUGM{Si2LSTDjc453\XK|aX;uJIFv\CCVUWPUUVEh\GWpcnHkZZRqd25? NUjzS3hTOjV5MUWwNlg>
HCT116 BAX BAK1 DKO M372cGZ2dmO2aX;uJGF{e2G7 NGDse3g{NzFyIN88US=> MkLuNVLDqGkEoB?= MYDEUXNQ M4TWNIlv\HWlZYOgZUBld3OnLXTldIVv\GWwdDDpcoNz\WG|ZTDpckBNSzOELVnJJINwdn[ncoPpc44h[W6mIGPRV3ROOSCmZXfyZYRifGmxbh?= NEH3[VIzPTdzNUCyPC=>
HCT116 NVOxOHRpTnWwY4Tpc44hSXO|YYm= MoLHNVAh|ryP NX3SVY1UOTMEoHlCpC=> MWHEUXNQ MVfpcoNz\WG|ZYOgS2ZRNUyFM1KgdJVv[3Sj MmrJNlU4OTVyMki=
HCT116 BAX BAK1 DKO NEHlZ2tHfW6ldHnvckBCe3OjeR?= MXmxNEDPxE1? MlzLNVLDqGkEoB?= Mki0SG1UVw>? NIPh[IhqdmO{ZXHz[ZMhT0[SLVzDN2IheHWwY4Th MYWyOVcyPTB{OB?=
HCT116 NFzaclNCfXSxcHjh[5khSXO|YYm= NGXWflYyOCEQvF2= NFi2NYQyOsLiaNMg MlfISG1UVw>? MULpcoR2[2W|IHGgZ49ueGyndHWgZZV1d3CqYXfpZ{Bz\XOyb37z[S=> NHTlXGIzPTdzNUCyPC=>
HCT116 BAX BAK1 DKO MlnURZV1d3CqYXf5JGF{e2G7 M1W3bVExKM7:TR?= M4PwRlEzyqCqwrC= M4m4TWROW09? MV7pcoR2[2W|IHGgZ49ueGyndHWgZZV1d3CqYXfpZ{Bz\XOyb37z[S=> M4rndVI2PzF3MEK4
U937 NGXMSJRCeG:ydH;zbZMhSXO|YYm= NX\2eY56OC5zMkWtNkDPxE1? NX7mR3FROjRiaB?= MXHlcohidmOnczDETGEwYC1zMT3pcoR2[2WmIHHwc5B1d3Orcx?= NY\KUVYyOjV5MUSwNlQ>
U937  NVrXV2Z{SXCxcITvd4l{KEG|c3H5 MnnFNE42KM7:TR?= NUDYW4FNOjRiaB?= NGnG[YZmdmijbnPld{BkdGWjdnHn[UBw\iCSQWLQJIFv\CClYYPwZZNmNTNiYYOge4VtdCCjczDOc5hiKGyndnXs M3e4UFI2PzF2MEK0
HL-60 AAA-Bcl-2 MknJRZBweHSxc3nzJGF{e2G7 MVqwMVUh|ryP NEDVTYw1QCCq NVS5bIFyUUN3ME2wMlg4KM7:bf-8kIlv\HWlZYOgZ4VtdCCjcH;weI9{cXNiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? M1SyWlI2PzFzNE[w
HL-60 EEE-Bcl-2 NYPsUpVZSXCxcITvd4l{KEG|c3H5 M4rqXlAuPSEQvF2= NHHnTFE1QCCq NXfZR5E1UUN3ME21JO69de,:jDDpcoR2[2W|IHPlcIwh[XCxcITvd4l{KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz M3rWXlI2PzFzNE[w
U87 MV3GeY5kfGmxbjDBd5NigQ>? MV[1NEDPxE1? Mlf3NlQhcA>? M3:4XZJm\HWlZYOgeIhmKG2UTlGg[ZhxemW|c3nvckBt\X[nbIOgc4YhVU2SLUKsJG1OWC1zNDDhcoQhSmOuLUK= MVWyOVY3PzZ4Mx?=
K562 NVewfJljS2WubDDWbYFjcWyrdImgRZN{[Xl? NX\JfVVXOS1zMDFOwG0> MVO0PEBp MoSySG1UVw>? NX:zXlc1UUN3ME2yOk44KM7:TR?= NXLRV3dFOjV3OU[1OlE>
K562/Mcl -1-IRESBim NFrxb|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV;Hb4JWUUN3ME25MlMh|ryP Mlj4NlU2OzV7MEC=
K562/Bcl- 2-IRESBim NUT1dmt[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHzt[nBKSzVyPUCuN|Uh|ryP NIn0bZEzPTV|NUmwNC=>
Jurkat MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEnMRmxKSzVyPUCuOlYh|ryP NVnuXGdrOjV3M{W5NFA>
JurkatΔBak M4LiV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mne3TWM2OD53MDFOwG0> NY[zbVlSOjV3M{W5NFA>
HL60/VCR NUflNpZxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVjreHh2UUN3ME6xNFAh|ryP MlLtNlU2OzV7MEC=
Kasumi-1 NYm4bHRGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX7LfFhxUUN3ME2wMlAyKM7:TR?= MnTpNlU2OzV7MEC=
Kasumi-1/ABT M1jGT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnfMTWM2OD1yLkWxJO69VQ>? M17IWFI2PTN3OUCw
THP-1 NGnMUJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIXXUZpKSzVyPUGuNlch|ryP M1OzZlI2PTN3OUCw
U937 Mn3pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWryUXd4UUN3ME21MlI6KM7:TR?= MkHpNlU2OzV7MEC=
C1498 NFz1elRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXPJR|UxRTZwMUOg{txO NV7XNld3OjV3M{W5NFA>
RPMI 8226 M1fzZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF:3e5dKSzVyPUCuNlUh|ryP NIDUcWczPTV|NUmwNC=>
MM.1S NWfyOpMzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUTJR|UxRTBwNECg{txO NX7uTHVtOjV3M{W5NFA>
NCI-H929 NEnOc5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1;hWGlEPTB;MUWuNlEh|ryP MlnPNlU2OzV7MEC=
U266 NFrWRW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mk\5TWM2OD1yLk[4JO69VQ>? NIH1ToEzPTV|NUmwNC=>
MCF-7 MoTuR4VtdCCYaXHibYxqfHliQYPzZZk> MXe1JO69VQ>? NGiwS3A1QCCq NGTMRpFFVVOR M2fKTYVvcGGwY3XzJJRp\SC|ZX7zbZRqfmm2eTD0c{BweiC{YXTpZZRqd25? MYmyOVQxQTF{NB?=
MCF-7 M1H1ZmFxd3C2b4Ppd{BCe3OjeR?= NUjNUHliPSEQvF2= MX:0M|I1NzR6IHi= NXXRUJFtTE2VTx?= M{GxeYlv[3KnYYPld{B1cGViY3zlZZZm\CCSQWLQ MWCyOVQxQTF{NB?=
MCF-7 MmLNSpVv[3Srb36gRZN{[Xl? M1jmN|Uh|ryP MViyOEBp M3nzfGROW09? NWftTIhy\W6qYX7j[ZMhfGinbHX2[Ywhd2ZiTXPsMVEh\XiycnXzd4lwdsLi NYL5TXoyOjV2MEmxNlQ>
MDA-MB 231  M3f4e2Z2dmO2aX;uJGF{e2G7 NVnVeFJ{PSEQvF2= NWrHVlVrOjRiaB?= NF;4N4NFVVOR MVvlcohidmOnczD0bIVt\X[nbDDv[kBO[2xvMTDlfJBz\XO|aX;uxsA> MmHrNlU1ODlzMkS=
ZR-75-1  NYDsRXFSTnWwY4Tpc44hSXO|YYm= MVy1JO69VQ>? Ml\YNlQhcA>? MnPYSG1UVw>? M1HsboVvcGGwY3XzJJRp\WyndnXsJI9nKE2lbD2xJIV5eHKnc4Ppc47DqA>? NYn2e5ZYOjV2MEmxNlQ>
A549 MnTiR4VtdCCYaXHibYxqfHliQYPzZZk> Mo\vNE0zOCEQvF2= MVK3NkBp MUnEUXNQ NWXaS2M2\GWlcnXhd4V{KHSqZTDj[YxtKHO3co\peoFtKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVzKGOxbXLpcoVlKHerdHigZZNxcXKrbh?= M{XDflI2Ozh6N{[y
H1299 NIT4WG9E\WyuIG\pZYJqdGm2eTDBd5NigQ>? MY[wMVIxKM7:TR?= MlywO|IhcA>? NH3PXYlFVVOR MV;k[YNz\WG|ZYOgeIhmKGOnbHygd5Vzfmm4YXygbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYKgZ49u[mmwZXSge4l1cCCjc4Dpdolv NUDEUGU{OjV|OEi3OlI>
HO-8910 NULiUFFFS2WubDDWbYFjcWyrdImgRZN{[Xl? MkjqNE0zOCEQvF2= Mo\6O|IhcA>? NWLOdXRnTE2VTx?= M1XnWIRm[3KnYYPld{B1cGViY3XscEB{fXK4aY\hcEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldkBkd22kaX7l[EB4cXSqIHHzdIlzcW5? NW\2b2hWOjV|OEi3OlI>
HT-29 NGnw[4xE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MX6wMVIxKM7:TR?= M2[wWlczKGh? MV3EUXNQ M1XyeIRm[3KnYYPld{B1cGViY3XscEB{fXK4aY\hcEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldkBkd22kaX7l[EB4cXSqIHHzdIlzcW5? NIfwSYEzPTN6OEe2Ni=>
HCT-116 M{LqbWNmdGxiVnnhZoltcXS7IFHzd4F6 M1LEZlAuOjBizszN NViwbXFxPzJiaB?= M1S1d2ROW09? NFXqe2tl\WO{ZXHz[ZMhfGinIHPlcIwhe3W{dnn2ZYwhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZIh[2:vYnnu[YQhf2m2aDDhd5Bqemmw NUDHNJN3OjV|OEi3OlI>
A549 NV;lTnFKSXCxcITvd4l{KEG|c3H5 NFj3W5ozOCEQvF2= M4nzZlQ5KGh? M2PqNWROW09? MYTpcoR2[2W|IHHwc5B1d3OrczDzbYdvcW[rY3HueIx6KGOxbXLpcoVlKHerdHigZZNxcXKrbh?= NIrTe20zPTN6OEe2Ni=>
H1299 NXXuWWJ3SXCxcITvd4l{KEG|c3H5 Mk\uNlAh|ryP M4jJWVQ5KGh? MVXEUXNQ MYLpcoR2[2W|IHHwc5B1d3OrczDzbYdvcW[rY3HueIx6KGOxbXLpcoVlKHerdHigZZNxcXKrbh?= M4nhTlI2Ozh6N{[y
Sc-1 NFHBTWhE\WyuIG\pZYJqdGm2eTDBd5NigQ>? M2SyTFAvODByMT2xJO69VQ>? NWSx[4JoQTZiaB?= M4i2VIRm[3KnYYPld{B1cGViY3XscEB3cWGkaXzpeJkhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> NGe5bmIzPTN5M{WwPC=>
OcI-LY18 NY\Kb41KS2WubDDWbYFjcWyrdImgRZN{[Xl? MVmwMlAxODFvMTFOwG0> NVfuVpV4QTZiaB?= NWP5UJRo\GWlcnXhd4V{KHSqZTDj[YxtKH[rYXLpcIl1gSCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? M1Lp[VI2Ozd|NUC4
RL  MXTD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MUewMlAxODFvMTFOwG0> MYm5OkBp MoXz[IVkemWjc3XzJJRp\SClZXzsJJZq[WKrbHn0fUBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> NUTKcmI4OjV|N{O1NFg>
RKO NXTRS4FzS2WubDDWbYFjcWyrdImgRZN{[Xl? M2\SWVAuOTBizszN MoX2NlTjiImqwrC= NI\OWllFVVOR M{jtemlEPTB-4pEJNlXjiIoEtV2= NYLVRW5XOjV|MESzPFM>
Caco-2 MYnD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NVXZSG5ZOC1zMDFOwG0> MlTDNlTjiImqwrC= MkHrSG1UVw>? NVzDfppkUUN3ME2xPU446oDLwsXN Mk\LNlU{ODR|OEO=
DLD1 NELMTHRE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MXiwMVExKM7:TR?= MY[yOQKBkWkEoB?= NHnuU|lFVVOR M4TS[WlEPTB;MUiuO|jjiIoEtV2= NUf0dnQ6OjV|MESzPFM>
LS411N MorSR4VtdCCYaXHibYxqfHliQYPzZZk> NXLQS3BLOC1zMDFOwG0> MoXnNlTjiImqwrC= M1HTO2ROW09? NFPpRYxKSzVyPUGxMlQ46oDLwsXN Mn;mNlU{ODR|OEO=
SW620 NGD2fmxE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MX:wMVExKM7:TR?= MoDzNlTjiImqwrC= MYTEUXNQ NGLFOmJKSzVyPUGyMlI16oDLwsXN MU[yOVMxPDN6Mx?=
HCT116 NHrCSYRE\WyuIG\pZYJqdGm2eTDBd5NigQ>? Mon5NE0yOCEQvF2= MmX3NlTjiImqwrC= M3qwSGROW09? NI\lVlFKSzVyPUKwMlQ66oDLwsXN MkfrNlU{ODR|OEO=
HaCaT NIC1OpBE\WyuIG\pZYJqdGm2eTDBd5NigQ>? M2jPTVAvOS9zL{GwJO69VQ>? NHG4OWIzPCCq M{C3PGROW09? NYG3cFJS\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy M37m[FI2OjFyN{m1
A5-RT3 MXPD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MXqwMlEwOS9zMDFOwG0> MkLCNlQhcA>? Mk\LSG1UVw>? MYrk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NXTveIpyOjV{MUC3PVU>
HaCaT NUHqWVJVTnWwY4Tpc44hSXO|YYm= NYTDOWVqOTEkgJpOwG0> NXPiTo84OjRxNEigbC=> MUTEUXNQ NFrzV4NqdmS3Y3XzJG1OWCCjbnSgSG5CKG[{YXft[Y51[XSrb36= NITq[HkzPTJzMEe5OS=>
A5-RT3 MnvKSpVv[3Srb36gRZN{[Xl? M4nsTlEx6oDLzszN Mof4NlQwPDhiaB?= NEeyRWFFVVOR M1zN[Ylv\HWlZYOgUW1RKGGwZDDEUmEh\nKjZ33lcpRifGmxbh?= MVWyOVIyODd7NR?=
A5-RT3 MX\GeY5kfGmxbjDBd5NigQ>? MlfBOUDPxE1? NH\PepY3KGh? NYjzZ2pbTE2VTx?= NFLUW41qdmS3Y3XzJJRp\SC{ZXzlZZNmKG:oIH3peI9kcG:wZILpZYwheHKxdHXpcpMh[W6mIILl[JVk\XNiY3zvco9o\W6rYzDzeZJ3cX[jbDDpckBiKGOjc4Dhd4UucW6mZYDlcoRmdnRibXHucoVz MoDmNlUzOTB5OUW=
U266 MVLGeY5kfGmxbjDBd5NigQ>? MXq1NFAwPzVyIH7N MU[yOE81QCCq M1vxSmROW09? Mknn[I94dnKnZ4XsZZRmeyCEaX2sJJBzcW6laYDhcIx6KHSqZTDFUEBqe2:ob4Lt NHHRSY8zPTJyOEi4PC=>
RPMI8226 NF[2VHBHfW6ldHnvckBCe3OjeR?= MVu1NFAwPzVyIH7N NFznd|IzPC92ODDo M3zRW2ROW09? MVPkc5dvemWpdXzheIV{KEKrbTygdJJqdmOrcHHscJkhfGinIFXMJIl{d2[xcn2= M2XjV|I2OjB6OEi4
MM.1S M3\ISGZ2dmO2aX;uJGF{e2G7 MkTpOVAxNzd3MDDuUS=> NWry[Zk1OjRxNEigbC=> MmP6SG1UVw>? MkPn[I94dnKnZ4XsZZRmeyCEaX2sJJBzcW6laYDhcIx6KHSqZTDFUEBqe2:ob4Lt M1voNVI2OjB6OEi4
Clone A Mk\qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnPUNE4z6oDVNkCg{txO MV63NkBp MojsSG1UVw>? NYnYWlE2UUN3ME23MlUh|ryP MWeyOVIxQDh6Mh?=
CX-1 MnrsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NETFSZMxNjMkgKO2NEDPxE1? MYG3NkBp M4\iZmROW09? NXnWbGVmUUN3ME2xMlgh|ryP NHrIPWczPTJyOEi4Ni=>
LS174T MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVjTWWRNOC5{4pETOlAh|ryP M2\OWlczKGh? Mn:zSG1UVw>? MXfJR|UxRTF6LkOg{txO MYGyOVIxQDh6Mh?=
HT29 MXTBdI9xfG:|aYOgRZN{[Xl? MV[xM|UwOTBizszN MkfvOFghcA>? MYDjZZV{\XNiY3XscEBl\WG2aDDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= MkH6NlUyQTJzOEi=
SW480 MkT1RZBweHSxc3nzJGF{e2G7 MX2xM|UwOTBizszN M3\VT|Q5KGh? NVHBUpdn[2G3c3XzJINmdGxiZHXheIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> Mln3NlUyQTJzOEi=
Colo205 NUS0VpJvSXCxcITvd4l{KEG|c3H5 NXfSdo5OOS93L{GwJO69VQ>? MkLvOFghcA>? MVfjZZV{\XNiY3XscEBl\WG2aDDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NHP0S2wzPTF7MkG4PC=>
Caco2 M3rxTWFxd3C2b4Ppd{BCe3OjeR?= Ml7KNU82NzFyIN88US=> NH7hRmo1QCCq MXvjZZV{\XNiY3XscEBl\WG2aDDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NYXlXGlGOjVzOUKxPFg>
PCI-13 M4LLe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mnq3O|IhcA>? NHracWVFVVOR MlnhS2k2OD1zNTFCtUAyNjhizszN NEj2N3czPTF|OUO4Oy=>
PCI-15B NFXSRVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHPXNGQ4OiCq MXXEUXNQ MX3HTVUxRTFzINMxJFQvPSEQvF2= MXeyOVE{QTN6Nx?=
UM-SCC22B NUm4R|llT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV2yOGVSPzJiaB?= MYTEUXNQ M4TtbmdKPTB;MUmgxtEhOi57IN88US=> M{O4elI2OTN7M{i3
UM-SCC47 MlnQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1[3N|czKGh? M1;DWGROW09? M1\RU2dKPTB;MUmgxtEhOTJwMzFOwG0> NGnZPHczPTF|OUO4Oy=>
93-VU-147T MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUm3NkBp NFrRfnBFVVOR M1niW2dKPTB;ND6zJOKyKDNwNTFOwG0> Mk\DNlUyOzl|OEe=
UD-SCC2 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlPwO|IhcA>? MnzsSG1UVw>? M4jXN2dKPTB;MkigxtEhOi57IN88US=> MnHXNlUyOzl|OEe=
UPCI:SCC90 NV\UUpg4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVvDNZBlPzJiaB?= NHmyfWNFVVOR MYjHTVUxRTZwNjFCtUAyNjVizszN NX7selRxOjVzM{mzPFc>
RPMI-8226  M{SzV2NmdGxiVnnhZoltcXS7IFHzd4F6 NEPad4cyOjVxMkWwM|UxOCCwTR?= MXO0PIjDqA>? NInWWm5FVVOR Mkjo[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ MnuxNlUxODh{MEK=
OPM-2  MUjD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MnW4NVI2NzJ3MD:1NFAhdk1? NXO4b5FwPDiqwrC= NUDRWWhNTE2VTx?= MnrM[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ NVXObIhsOjVyMEiyNFI>
RPMI-8226  NV3rXYxMSXCxcITvd4l{KEG|c3H5 Mln2NVI2NzJ3MD:1NFAhdk1? NI\4[mc1QGkEoB?= NHHtRXpFVVOR MWjpcoR2[2W|IHPlcIwh[XCxcITvd4l{KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz MUSyOVAxQDJyMh?=
OPM-2  NWnr[FJsSXCxcITvd4l{KEG|c3H5 M1XJWlEzPS9{NUCvOVAxKG6P M3SxNlQ5cMLi M2\zfmROW09? MnuzbY5lfWOnczDj[YxtKGGyb4D0c5NqeyCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? NFiyWHYzPTByOEKwNi=>
COG-LL-319 NHTsPFhHfW6ldHnvckBCe3OjeR?= NUTOfFh4OTByIH7N NX;ofFFpOS9|L{[gbC=> NVnUPHpjTE2VTx?= M2LK[Ylv\HWlZYOgZ4F{eGG|ZT3k[ZBmdmSnboSgUYNtNTFiY3zlZZZi\2V? NGXsfYwzPDl3MUS3Ni=>
RS4;11 MkfpSpVv[3Srb36gRZN{[Xl? NWXJUJJZOTByIH7N NVrXfmc5OS9|L{[gbC=> MXTEUXNQ MnfrbY5lfWOnczDjZZNx[XOnLXTldIVv\GWwdDDNZ4wuOSClbHXheoFo\Q>? M4Pjc|I1QTVzNEey

... Click to View More Cell Line Experimental Data

In vivo In aggressive leukemia model, ABT-737 suppresses the leukemia burden by 53% at the 30 mg/kg, with significantly extended survival of mice. ABT-737 does not induce significantly abnormalities in blood cell counts or serum chemistries. [1] ABT-737 prolongs the survival of recipient mice transplanted with Bcl-2-transduced tumors. [2] ABT-737 shows great antitumor activity in an ATLL mouse model at a dose of 100 mg/kg. [5]

Protocol

Kinase Assay:

[1]

+ Expand

Fluorescence polarization assays:

Binding affinity of GST-Bcl-2 family proteins to the FITC-conjugated BH3 domain of Bim (FITC-Ahx-DMRPEIWIAQELRRIGDEFNAYYAR) is determined. Briefly, 100 nM of GST-Bcl-2 family fusion proteins are incubated with serial dilutions of ABT-737 in PBS for 2 min. Then, 20 nM of FITC-Bim BH3 peptide (FITC-Ahx-DMRPEIWIAQELRRIGDEFNAYYAR) is added. Fluorescence polarization is measured using an Analyst TM AD Assay Detection System after 10 min using the 96-well black plate. Then IC50 are determined.
Cell Research:

[4]

+ Expand
  • Cell lines: SCLC cell lines NCI-H889, NCI-H1963, NCI-H1417, NCI-H146, NCI-187, DMS79, NCI-1048, NCI-H82, NCI-H196, H69AR, and DMS114
  • Concentrations: 0.001-10 μM
  • Incubation Time: 48 hours
  • Method:

    SCLC cells are treated for 48 hours in 96-well tissue culture plates in a total volume of 100 μL tissue culture medium supplemented with 10% human serum. Viable cells are determined using the MTS assay.


    (Only for Reference)
Animal Research:

[1]

+ Expand
  • Animal Models: Scid mice injected with Luc-expressing FD/ΔRaf-1:ER cells
  • Formulation: 1 g/mL stock solution of ABT-737 in DMSO is added to a mixture of 30% propylene glycol, 5% Tween 80, 65% D5W (5% dextrose in water) (pH 4−5; final concentration of DMSO ≤ 1%)
  • Dosages: 20 and 30 mg/kg
  • Administration: For intraperitoneal (i.p.) every day
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 100 mg/mL (122.93 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order:
30% Propylene glycol, 5% Tween 80, 65% D5W
For best results, use promptly after mixing.
30mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 813.43
Formula

C42H45ClN6O5S2

CAS No. 852808-04-9
Storage powder
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    What’s the recommended method about reconstitution of the compound for in vivo animal study?

  • Answer:

    For oral administration, we suggest the vehicle: 30% Propylene glycol, 5% Tween 80, 65% D5W, at up to 30mg/ml; For injection, ABT-737 can be dissolved in 2% DMSO/50% PEG 300/5% Tween 80/ddH2O at 2.5 mg/ml.

Bcl-2 Signaling Pathway Map

Bcl-2 Inhibitors with Unique Features

Related Bcl-2 Products

Tags: buy ABT-737 | ABT-737 supplier | purchase ABT-737 | ABT-737 cost | ABT-737 manufacturer | order ABT-737 | ABT-737 distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID